期刊文献+

特利加压素联合大剂量白蛋白治疗肝硬化肝肾综合征的疗效观察 被引量:11

Observation of terlipressin with albumin infusion in management of patients with hepatorenal syndrome
下载PDF
导出
摘要 目的观察特利加压素及其联合大剂量白蛋白治疗肝肾综合征的疗效。方法53例患者分为三组,在综合治疗的基础上,A组使用多巴胺,B组使用特利加压素,C组使用特利加压素联合大剂量白蛋白,治疗期间观察患者临床症状、尿量、血肌酐、腹水消长情况,终止治疗事件及治疗后的转归。结果B、C组尿量、肌酐清除率显著增加,血肌酐降低,且C组变化比B组明显,A组仅轻度改善,三组间比较有显著差异。结论特利加压素对肝肾综合征的治疗有确切的疗效,大剂量白蛋白扩容可提高特利加压素对肾功能的作用。 Objective To observe the effect of terlipressin with large dose of albumin in management of patients with hepatorenal syndrome. Methods 53 patients were divided into three groups and in group A, low-dose of dopamine were used, in group B terlipressin were used and terlipressin with large dose of albumin was used in group C. The clinical symptoms, the total urine output and serum creatinine level were observed during treatment. Result In group B and group C, the total urine output and serum creatinine clearing test were increased significantly; the serum creatinine level were decreased remarkably. The patients in group C achieved better effect than that in group 13. Conclusion Terlipressin is effective on hepatorenal syndrome. Terlipressin with large dose of albumin can get enhanced results.
出处 《实用肝脏病杂志》 CAS 2007年第2期98-101,共4页 Journal of Practical Hepatology
关键词 肝肾综合征 肝硬化 特利加压素 白蛋白 Hepatorenal syndrome Terlipressine Albumin Liver cirrhosis
  • 相关文献

参考文献13

  • 1GINES P,GUEVARA M,ARROYO V,et al.Hepatorenal syndrome[J].Lancet,2003,362:1819-1827. 被引量:1
  • 2Jian Huang Mei-Ying Cai Da-Peng Wei Immunology Department,West China University of Medical Sciences,Chengdu 610044,Sichuan Province,China.HLA class Ⅰ expression in primary hepatocellular carcinoma[J].World Journal of Gastroenterology,2002,8(4):654-657. 被引量:33
  • 3ARROYO V,GINES P,GERBES A,et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites clubs[J].Hepatology,1996,23:164-173. 被引量:1
  • 4BATALLER R,SORT P,GINES P,et al.Hepatorenal syndrome:Definition,pathophysiology,clinical features and management[J].Kidney Int Suppl,1998,66:47-53. 被引量:1
  • 5HALIML C,BONNARD P,BERNARD B,et al.Effect of terlipressin on hepatorenal syndrome in cirrhotic patients:results of a multicentre pilot study[J].Eur J Gastroenterol Hepatol,2002,14:153-158. 被引量:1
  • 6ALESSANDRIAL C,VENON WD,MARZANO A,et al.Renal failure in cirrhotic patients:role of terlipressin in clinical approach to hepatorenal syndrome type 2[J].Eur J Gastroenterol Hepatol,2002,14:1363-1368. 被引量:1
  • 7COLLE I,DURAND F,PESSIONE F,et al.Clinical courses,predicitive factors and prognosis in patients with cirrhosis and type Ⅰ hepatorenal syndrome treated with terlipressin:a retrospective ananlysis[J].J Gastroenterol Hepatol,2002,17:882-888. 被引量:1
  • 8SOLANKI P,CHAWLA A,GARG R,et al.Beneficial effects of terlipressin in hepatorenal syndrome:A prospective,randomized placebo-controlled clinical trial[J].J Gastroenterol Hepatol,2003,18:152-156. 被引量:1
  • 9GULBERG V,BILZER M,GERBES AL,et al.Longterm therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine[J].Hepatology,1999,30:870-875. 被引量:1
  • 10ORTEGA R,GINES P,URIZ J,et al.Terlipressin therapy with and without albumin for patients with hep atorenal syndrome.Results of a prospective,non-randomized study[J].Hepatology,2002,36::941-948. 被引量:1

二级参考文献10

  • 1Paroli M,Carloni G,Franco A,De Petrillo G,Alfani E,Perrone A,Barnaba V.Human hepatoma cells expressing MHC antigens display accessory cell function,dependence on LFA-1/ICAM-1 interaction[].Immunology.1994 被引量:1
  • 2Ruiz-Cabello F,Garrido F.HLAand cancer:Fromresearch to clinical impact[].Immunology Today.1998 被引量:1
  • 3Sung CH,Hu CP,Hsu HC,Ng AK,Chou CK,Ting LP,Su TS,Han SH,Chang CM.Expression of class Ⅰ and class Ⅱ major histocompatibility antigens on human hepatocellular carcinoma[].The Journal of Clinical Investigation.1989 被引量:1
  • 4Wadee A A,Paterson A,Coplan KA,Reddy SG.HLA expression in hepatocellular carcinoma lines[].Clinical and Experimental Immunology.1994 被引量:1
  • 5Alexander,JJ,Bey,EM,Geddes,EW,Lecatsas,G.Establishment of a continuously growing cell line from primary carcinoma of the liver[].South African Medical Journal.1976 被引量:1
  • 6Aden,DP,Fogel,A,Plotkin,S,Damjanov,I,Knowles,BB.Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line[].Nature.1979 被引量:1
  • 7Jr,Vollmer,CM,Eilber,FC,Butterfield,LH,Ribas,A,Dissette,VB,Koh,A,Montejo,LD,Lee,MC,Andrews,KJ,McBride,WH,Glaspy,JA,Economou,JS.Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma[].Cancer Research.1999 被引量:1
  • 8Butterfield,LH,Koh,A,Meng,W,Vollmer,CM,Ribas,A,Dissette,V,Lee,E,Glaspy,JA,McBride,WH,Economou,JS.Generation of Human T-cell Responses to an HLA-A2.1-restricted peptide epitope derived from alpha-Fetoprotein[].Cancer Research.1999 被引量:1
  • 9Butterfield L,Meng W,Koh A,et al.T cell responses to HLA-A* 0201-restricted peptides derived from human alpha-fetoprotein[].J Immunol.2001 被引量:1
  • 10Paterson AC,Sciot R,Kew MC,Callea F,Dusheiko GM,Desmet VJ.HLA expression in human hepatocellular carcinoma[].British Journal of Cancer.1988 被引量:1

共引文献32

同被引文献81

引证文献11

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部